R1 RCM Inc. (NASDAQ:RCM) is Bardin Hill Management Partners LP’s 8th Largest Position

Bardin Hill Management Partners LP lifted its position in R1 RCM Inc. (NASDAQ:RCM) by 98.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 525,211 shares of the healthcare provider’s stock after buying an additional 260,891 shares during the period. R1 RCM comprises 2.7% of Bardin Hill Management Partners LP’s portfolio, making the stock its 8th largest holding. Bardin Hill Management Partners LP’s holdings in R1 RCM were worth $6,597,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in RCM. Advisors Asset Management Inc. purchased a new stake in shares of R1 RCM during the first quarter valued at $27,000. ANTIPODES PARTNERS Ltd bought a new position in R1 RCM during the 2nd quarter valued at about $86,000. QRG Capital Management Inc. purchased a new stake in shares of R1 RCM during the 1st quarter valued at about $132,000. Caas Capital Management LP bought a new stake in shares of R1 RCM in the fourth quarter worth approximately $148,000. Finally, CIBC Asset Management Inc bought a new stake in shares of R1 RCM in the second quarter worth approximately $149,000. Hedge funds and other institutional investors own 61.10% of the company’s stock.

Wall Street Analyst Weigh In

RCM has been the topic of several research reports. Canaccord Genuity Group restated a “buy” rating and issued a $15.00 target price on shares of R1 RCM in a report on Monday, July 22nd. Leerink Partnrs downgraded R1 RCM from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. Truist Financial reduced their price objective on R1 RCM from $16.00 to $14.30 and set a “hold” rating for the company in a research report on Thursday, August 8th. Stephens cut R1 RCM from an “overweight” rating to an “equal weight” rating in a research report on Thursday, August 1st. Finally, TD Cowen restated a “hold” rating and set a $14.30 price target (down from $20.00) on shares of R1 RCM in a research note on Monday, August 5th. Thirteen investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, R1 RCM has a consensus rating of “Hold” and an average target price of $15.41.

R1 RCM Trading Up 0.1 %

Shares of RCM opened at $14.18 on Wednesday. The stock has a market capitalization of $5.97 billion, a PE ratio of -177.25 and a beta of 0.84. The company’s fifty day moving average is $13.94 and its 200 day moving average is $13.01. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.84 and a current ratio of 1.84. R1 RCM Inc. has a fifty-two week low of $8.87 and a fifty-two week high of $15.26.

R1 RCM (NASDAQ:RCM) last released its quarterly earnings results on Wednesday, August 7th. The healthcare provider reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.03. The company had revenue of $627.90 million during the quarter, compared to analyst estimates of $633.10 million. R1 RCM had a negative return on equity of 1.44% and a negative net margin of 1.68%. The company’s quarterly revenue was up 12.0% on a year-over-year basis. Sell-side analysts expect that R1 RCM Inc. will post -0.24 earnings per share for the current fiscal year.

About R1 RCM

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.